drug

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic SyndromesOfirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes…

3 weeks ago
Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply ResilienceCambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience

Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a…

3 weeks ago
Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug DiscoveryLifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery

Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery

NORWALK, Conn., Oct. 9, 2025 /PRNewswire/ -- Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of…

1 month ago
Viva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery IndustryViva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

Viva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation…

1 month ago
Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for Probiotic Strain CP-9Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for Probiotic Strain CP-9

Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for Probiotic Strain CP-9

TAIPEI, Sept. 15, 2025 /PRNewswire/ -- Glac Biotech, a Taiwan-based developer of probiotics and postbiotics, announced that its core probiotic…

2 months ago
Saudi Food and Drug Authority, AAMI Partner on Medtech Best PracticesSaudi Food and Drug Authority, AAMI Partner on Medtech Best Practices

Saudi Food and Drug Authority, AAMI Partner on Medtech Best Practices

Arlington, Virginia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Association for the Advancement of Medical Instrumentation (AAMI) has signed a memorandum…

2 months ago
Helios Alliance Announces National Opioid Conference Featuring Former White House Drug Policy Director Dr. Rahul GuptaHelios Alliance Announces National Opioid Conference Featuring Former White House Drug Policy Director Dr. Rahul Gupta

Helios Alliance Announces National Opioid Conference Featuring Former White House Drug Policy Director Dr. Rahul Gupta

September 05, 2025 16:45 ET  | Source: Helios Alliance Mobile, Alabama , Sept. 05, 2025 (GLOBE NEWSWIRE) -- Helios Alliance,…

2 months ago
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular DystrophyKeros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

August 20, 2025 09:48 ET  | Source: Keros Therapeutics, Inc. LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics,…

3 months ago
AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic LaunchesAscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic Launches

AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic Launches

BERWYN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical…

4 months ago
ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHOArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report"…

4 months ago
Show more Posts